Response to levodopa in Parkinson's disease over time. A 4-year follow-up study

被引：2

作者：

Santos-Garcia, Diego ^{[1
,20
]}

Fonticoba, Teresa de Deus ^{[2
]}

Bartolome, Carlos Cores ^{[1
]}

Painceiras, Maria J. Feal ^{[1
]}

Diaz, Iago Garcia ^{[1
]}

Alvarado, Maria Cristina Iniguez

Paz, Jose Manuel ^{[1
]}

Jesus, Silvia ^{[3
,4
]}

Cosgaya, Marina ^{[5
]}

Caldentey, Juan Garcia ^{[6
]}

Caballol, Nuria ^{[7
]}

Legarda, Ines ^{[8
]}

Aramburu, Isabel Gonzalez ^{[3
,9
]}

Rivera, Maria A. Avila ^{[10
]}

Mayordomo, Victor Gomez ^{[11
]}

Vela, Lydia ^{[12
]}

Escalante, Sonia ^{[13
]}

Mendoza, Zebenzui ^{[14
]}

Castrillo, Juan C. Martinez ^{[15
]}

Alonso, Pilar Sanchez ^{[16
]}

Losada, Maria G. Alonso ^{[17
]}

Ariztegui, Nuria Lopez ^{[18
]}

McAfees, Darrian ^{[19
]}

Mir, Pablo ^{[4
]}

Martinez-Martin, Pablo

机构：

[1] Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain

[2] Complejo Hosp Univ Ferrol, CHUF, La Coruna, Spain

[3] Univ Seville, Hosp Univ Virgen Rocio, Serv Neurol & Neurofisiol Clin, Unidad Trastornos Movimiento,Inst Biomed Sevilla,C, Seville, Spain

[4] CIBERNED Ctr Invest Biomed Red Enfermedades Neurod, Madrid, Spain

[5] Hosp Clin Barcelona, Barcelona, Spain

[6] Ctr Neurol Oms 42, Palma De Mallorca, Spain

[7] Hosp Moises Broggi, Consorci Sanitari Integral, Barcelona, Spain

[8] Hosp Univ Son Espases, Palma De Mallorca, Spain

[9] Hosp Univ Marques Valdecilla IDIVAL, Santander, Spain

[10] Hosp Gen Hosp, Consorci Sanit Integral, Barcelona, Spain

[11] Vithas Madrid La Milagrosa Univ Hosp, Vithas Hosp Grp, Inst Neurosci, Neurol Dept, Madrid, Spain

[12] Fdn Hosp Alcorcon, Madrid, Spain

[13] Hosp Tortosa Verge La Cinta HTVC, Tortosa, Tarragona, Spain

[14] Hosp Univ Canarias, Santa Cruz De Tenerife, Spain

[15] Hosp Univ Ramon Y Cajal, IRYCIS, Madrid, Spain

[16] Hosp Univ Puerta Hierro, Madrid, Spain

[17] Complejo Hosp Univ Vigo CHUVI, Hosp Alvaro Cunqueiro, Vigo, Spain

[18] Complejo Hosp Toledo, Toledo, Spain

[19] Univ Maryland, Sch Med, College Pk, MD USA

[20] Complejo Hosp Univ A Coruna CHUAC, Hosp Univ A Coruna HUAC, Dept Neurol, C As Xubias 84, La Coruna 15006, Spain

来源：

PARKINSONISM & RELATED DISORDERS | 2023年 / 116卷

关键词：

Levodopa; Motor fluctuations; Off state; On state; Parkinson's disease; MOTOR RESPONSE; FLUCTUATIONS; EVOLUTION;

D O I：

10.1016/j.parkreldis.2023.105852

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background and objective: A good response to levodopa is a key factor to indicate device-aided therapies in people with Parkinson's disease (PwPD). The aim of the present study was to analyze the response to levodopa in PwPD with motor fluctuations followed for 4 years.Patients and methods: PwPD with motor fluctuations recruited from January 2016 to November 2017 from the COPPADIS cohort and assessed annually (from baseline to 4-year follow-up) during the OFF and ON states were included in this analysis. At each visit, the Unified Parkinson's Disease Rating Scale - part III (UPDRS-III) was applied during the OFF state (without medication during the last 12 h) and during the ON state. General linear model repeated measures were used to test for changes in the mean UPDRS-III-OFF, UPDRS-III-ON, and AUPDRS-III (UPDRS-III-OFF - UPDRS-III-ON) between visits. Levodopa equivalent daily dose (LEDD) was included as covariate.Results: Sixty-three patients (63.94 +/- 8.42 years old; 68.3% males) were included. Mean disease duration was 7.81 +/- 3.64 years. From baseline to 4-year follow-up visit, a significant increase in both the UPDRS-III-OFF (from 27.98 +/- 9.58 to 31.75 +/- 12.39; p = 0.003) and the UPDRS-III-ON (from 15.92 +/- 7.93 to 18.84 +/- 8.17; p = 0.006) was observed despite the significant increase in the LEDD (from 896.35 +/- 355.65 to 1085.51 +/- 488.29; p = 0.003). However, no significant differences were detected between visits in the AUPDRS-III. Conclusion: In this cohort of PwPD with motor fluctuations, the response to levodopa did not weaken after a 4 -year follow-up.

引用

页数：10

共 12 条

[11] COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global -clinical evaluations, serum biomarkers, genetic studies and neuroimaging- prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression
Santos-Garcia, Diego
Mir, Pablo
Cubo, Esther
Vela, Lydia
Cruz Rodriguez-Oroz, Mari
Jose Marti, Maria
Matias Arbelo, Jose
Infante, Jon
Kulisevsky, Jaime
Martinez-Martin, Pablo
[J]. BMC NEUROLOGY, 2016, 16
[12] Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide
Schade, Sebastian
Mollenhauer, Brit
Trenkwalder, Claudia
[J]. MOVEMENT DISORDERS CLINICAL PRACTICE, 2020, 7 (03): : 343 - 345

← 1 2 →